Update (9:37 a.m.): Updated with Tuesday market open information.
NEW YORK (TheStreet) -- Credit Suisse downgraded Allergan (AGN) to "neutral" from "outperform" and set a $190 price target. The firm noted risk/reward is balanced, following the latest bid from Valeant (VRX).
The stock was down 0.79% to $170.88 at 9:36 a.m. on Tuesday.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts